Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrrolate for PONV after ERCP
NCT06045364Phase 2Completed
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in postoperative nausea and vomiting (PONV) (2 arms). Primary endpoint: Incidence of postoperative nausea and vomiting. Started Oct 2023; status: completed.
02
Drugs
glycopyrronium
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06045364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045364.